From Lab to Market — Commercialize AeroFoam-7 at NorTec Transfer Office

A four-round, advanced technology-transfer simulation set inside NorTec Transfer Office, the knowledge-transfer unit of a Porto-based research university operating from the U.Porto innovation ecosystem (EUR 1.8M annual budget, six-person team, 23 disclosed inventions). Two clocks collide on 16 June 2026: AeroFoam-7 — a recyclable aerogel insulation material with strong lab data but stuck at Technology Readiness Level 4 — must enter the PCT patent national phase within 90 days (≈EUR 180,000) or lose protection in key markets, and the same quarter the discretionary EUR 600,000 proof-of-concept seed fund's reporting period closes, clawing back anything unspent. Industrial buyers want TRL 7, and closing the valley of death needs ≈EUR 450,000 plus 9–12 months of field validation — so internal money alone cannot both protect and de-risk the asset and external leverage is mandatory. Playing the Tech-Transfer Manager you (1) diagnose readiness and value honestly, naming the binding constraint as the TRL-4-to-7 readiness gap rather than treating lab data as sale-ready; (2) choose the commercialization model — exclusive license, inventor spin-off, or a co-funded joint-development agreement — matching pathway to the technology's maturity, the lead inventor's reluctance to leave academia, and the capital available; (3) allocate the EUR 600k seed fund across national-phase filing, field validation and a reserve, decide which jurisdictions to file in versus abandon, and pick a partner among a multinational's EUR 250k + 3% royalty exclusive license, a regional construction group's EUR 400k co-funded JDA with a future option, or a venture fund's EUR 1.2M for 35% equity conditional on the inventor leaving; and (4) sequence the next 12 months around the hard deadlines, set exit KPIs, and build a contingency for inventor exit or weak validation. The math rewards genuine funding leverage (≥1.5× external euros per internal euro), context-fit pathway choice and deadline-driven sequencing, and punishes the five classic errors — upside-chasing into a founderless spin-off, leverage blindness, control surrender to a conflicted incumbent, IP over-filing, and readiness denial. Final KPIs track Readiness (TRL progress), Funding Leverage, Value Capture and seed-fund Budget used against the EUR 600k cap.